<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">114930</article-id><article-id pub-id-type="doi">10.17816/clinpract114930</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Efficacy of two-stage approach for interventional treatment of coexistent atrial fibrillation and typical atrial flutter for sinus rhythm maintenance in long-term: a prospective controlled clinical trial</article-title><trans-title-group xml:lang="ru"><trans-title>Отдалённые результаты двухэтапного подхода к интервенционному лечению сопутствующих фибрилляции и типичного трепетания предсердий: проспективное контролируемое клиническое исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9247-4523</contrib-id><contrib-id contrib-id-type="spin">6338-4990</contrib-id><name-alternatives><name xml:lang="en"><surname>Khamnagadaev</surname><given-names>Igor A.</given-names></name><name xml:lang="ru"><surname>Хамнагадаев</surname><given-names>Игорь Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>i@khamnagadaev.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8195-5682</contrib-id><contrib-id contrib-id-type="spin">5024-6323</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovalev</surname><given-names>Igor A.</given-names></name><name xml:lang="ru"><surname>Ковалёв</surname><given-names>Игорь Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>igor.kovalev64@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6267-3724</contrib-id><contrib-id contrib-id-type="spin">1275-2773</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulavina</surname><given-names>Irina A.</given-names></name><name xml:lang="ru"><surname>Булавина</surname><given-names>Ирина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>doctoroirb@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4766-5213</contrib-id><name-alternatives><name xml:lang="en"><surname>Kokov</surname><given-names>Mikhail L.</given-names></name><name xml:lang="ru"><surname>Коков</surname><given-names>Михаил Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mikhailkokov@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0494-0211</contrib-id><contrib-id contrib-id-type="spin">9315-6570</contrib-id><name-alternatives><name xml:lang="en"><surname>Zotov</surname><given-names>Aleksandr S.</given-names></name><name xml:lang="ru"><surname>Зотов</surname><given-names>Александр Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>zotov.alex.az@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2143-8696</contrib-id><contrib-id contrib-id-type="spin">2670-6662</contrib-id><name-alternatives><name xml:lang="en"><surname>Troitskiy</surname><given-names>Aleksandr V.</given-names></name><name xml:lang="ru"><surname>Троицкий</surname><given-names>Александр Витальевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>dr.troitskiy@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8541-0364</contrib-id><contrib-id contrib-id-type="spin">6883-5175</contrib-id><name-alternatives><name xml:lang="en"><surname>Khamnagadaev</surname><given-names>Igor I.</given-names></name><name xml:lang="ru"><surname>Хамнагадаев</surname><given-names>Игорь Иосифович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>khamnagadaev@edu.bsu.ru</email><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7115-0186</contrib-id><contrib-id contrib-id-type="spin">9051-7107</contrib-id><name-alternatives><name xml:lang="en"><surname>Shkolnikova</surname><given-names>Maria A.</given-names></name><name xml:lang="ru"><surname>Школьникова</surname><given-names>Мария Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>arrithmolog@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3167-3692</contrib-id><contrib-id contrib-id-type="spin">1655-5794</contrib-id><name-alternatives><name xml:lang="en"><surname>Kokov</surname><given-names>Leonid S.</given-names></name><name xml:lang="ru"><surname>Коков</surname><given-names>Леонид Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>д.м.н., профессор, академик РАН</p></bio><bio xml:lang="ru"><p>Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences</p></bio><email>lskokov@mail.ru</email><xref ref-type="aff" rid="aff7"/><xref ref-type="aff" rid="aff8"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Moscow City Clinical Hospital in honor of V.M. Buyanov</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница имени В.М. Буянова</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Russian State Agrarian University — Moscow Timiryazev Agricultural Academy</institution></aff><aff><institution xml:lang="ru">Российский государственный аграрный университет — Московская сельскохозяйственная академия имени К.А. Тимирязева</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Belgorod State National Research University</institution></aff><aff><institution xml:lang="ru">Белгородский государственный национальный исследовательский университет</institution></aff></aff-alternatives><aff-alternatives id="aff7"><aff><institution xml:lang="en">Sklifosovsky Research Institute of Emergency Medicine</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского</institution></aff></aff-alternatives><aff-alternatives id="aff8"><aff><institution xml:lang="en">Moscow State University of Medicine and Dentistry named after A.I. Evdokimov</institution></aff><aff><institution xml:lang="ru">Московский государственный медико-стоматологический университет имени А.И. Евдокимова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-03-10" publication-format="electronic"><day>10</day><month>03</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-07-02" publication-format="electronic"><day>02</day><month>07</month><year>2023</year></pub-date><volume>14</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>5</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2022-11-27"><day>27</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-21"><day>21</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/114930">https://clinpractice.ru/clinpractice/article/view/114930</self-uri><abstract xml:lang="en"><p><bold>Background:</bold> Atrial fibrillation (AF) and coexistent typical atrial flutter (AFL) interventional treatment strategy remains unresolved in cardiology and cardiovascular surgery. Results of this approach remain suboptimal. There are several approaches to the interventional treatment of patients with coexistent AF and AFL: simultaneous pulmonary vein isolation (PVI) and cavotricuspid isthmus (CTI) radiofrequency catheter ablation (RFCA), PVI or CTI RFCA only and two-stage approach. To our knowledge, cumulative efficacy of two-stage approach has not been previously reported.</p> <p><bold>The aim.</bold> This study aimed to evaluate the efficacy of two-stage approach for interventional treatment of coexistent AF and AFL for sinus rhythm maintenance in long-term.</p> <p><bold>Methods:</bold> Patients (pts) (n=34) with AF and AFL aged 41–82 years (11 women) were divided into two groups (1:1): «One-stage Approach» (group 1; n=17): PVI+СTI RFСA and «Two-stage approach» (group 2; n=17): first stage — CTI RFCA (group 2.1); second stage — PVI in case of AF recurrence after RFCA (group 2.2). Primary endpoint (PEP) was defined as any recurrent atrial tachyarrhythmia at the end of follow-up; group 2 events have been considered after PVI. Secondary endpoint (SEP) — recurrent any atrial tachyarrhythmia in groups 1 and 2 after CTI RFCA in group 2. PEP and SEP were evaluated at the end of the «blind period» (3 months after procedure).</p> <p><bold>Results:</bold> Registered recurrent atrial tachyarrhythmia in pts who reached PEP or SEP was AF. AFL has not been detected in any cases. PEP was noted in 8 (47.06%) pts in group 1 and 1 (5.88%) pts in group 2. Further, SEP was observed in 3 pts (17.65%) in group 1 and in 4 (23.53%) pts in group 2 (p=0.671). The probability of long-term maintenance of sinus rhythm was significantly higher in «Two-stage approach» than in «One-stage approach» (94.12% and 52.94%, respectively, p=0.001). Significant differences in procedure length and fluoroscopy time have been found. Those were longer in group 1 compared to group 2.1 (p &lt;0.001) and in group 2.2 compared to group 2.1 (procedure duration — p &lt;0.001; fluoroscopy time — p=0.013). No differences were noted in length of procedure and fluoroscopy time between groups 1 and 2.2 (p=0.374 and p=0.028, respectively).</p> <p><bold>Conclusion:</bold> The «two-stage approach» for interventional treatment of coexistent AF and AFL results in better long-term arrhythmia-free survival than «one-stage approach» (94.12% and 52.94%, respectively, p=0.001). CTI RFCA alone in pts with coexistent AF and AFL cause 23.53% AF recurrence rate and associated with shorter procedure duration and fluoroscopy time compared to simultaneous PVI and CTI RFCA (p &lt;0.001).</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Оптимизация подходов к интервенционному лечению сопутствующих фибрилляции предсердий (ФП) и типичного трепетания предсердий (ТП) является одной из важных проблем современной кардиологии и сердечно-сосудистой хирургии. При этом результаты лечения данной патологии остаются неудовлетворительными. В настоящее время стратегия интервенционного лечения сопутствующих ФП и типичного ТП не регламентирована, а выбор варианта лечения основан на предпочтениях хирурга и сложившейся практике в медицинской организации: катетерная изоляция лёгочных вен (ИЛВ) в сочетании с радиочастотной абляцией (РЧА) кавотрикуспидального перешейка (КТП), изолированное интервенционное лечение одного из нарушений ритма сердца или их двухэтапное устранение. Работы, которые оценивают отдалённые результаты двухэтапного лечения ФП и типичного ТП как единого процесса, в настоящее время не представлены.</p> <p><bold>Цель исследования</bold> — оценить эффективность длительного удержания синусового ритма при двухэтапном подходе к интервенционному лечению сопутствующих ФП и типичного ТП.</p> <p><bold>Методы.</bold> Пациенты (n=34) с ФП и типичным ТП в возрасте 41–82 лет (11 женщин) распределены на две группы (1:1). Группа 1 («Одноэтапный подход»; n=17): ИЛВ+РЧА КТП во время одной операции. Группа 2 («Двухэтапный подход»; n=17): «Первый этап» — РЧА КТП (группа 2.1), «Второй этап» — ИЛВ в случае рецидива ФП после РЧА КТП (группа 2.2). Первичная конечная точка: развитие любой предсердной тахикардии в период наблюдения. В группе 1 событие учитывалось после одномоментной ИЛВ и РЧА КТП. В группе 2 событие учитывалось после завершения второго этапа интервенционного лечения. Вторичная конечная точка: развитие любой предсердной тахикардии в группах 1 и 2 в период времени после завершения первого этапа интервенционного лечения (РЧА КТП) в группе 2. Первичная и вторичная конечные точки оценивались по окончанию «слепого периода» (3 месяца после операции).</p> <p><bold>Результаты.</bold> У всех пациентов, достигших первичную и вторичную конечную точку, диагностировалась только ФП. Типичное ТП и другие предсердные нарушения ритма сердца не зарегистрированы ни в одном случае. В группе 1 первичную конечную точку достигли 8 (47,06%) пациентов, в группе 2 — 1 (5,88%). При анализе кривых выживаемости выявлено, что вероятность длительного удержания синусового ритма статистически значимо выше в группе 2 («Двухэтапный подход») по сравнению с группой «Одноэтапный подход» (94,12 и 52,94% соответственно; p=0,001). При оценке вторичной конечной точки статистически значимых различий между группами 1 и 2 не выявлено (p=0,671). В группе 1 вторичную конечную точку достигли 3 (17,65%) пациента, в группе 2 — 4 (23,53%). При оценке продолжительности операции и времени рентгеноскопии выявлены статистически значимые различия: данные временные характеристики больше в группе 1 по сравнению с группой 2.1 (p &lt;0,001) и в группе 2.2 по сравнению с группой 2.1 (продолжительность операции — p &lt;0,001; время рентгеноскопии — p=0,013). Данные параметры статистически значимо не отличались в группах 1 и 2.2 (p=0,374 и p=0,028 соответственно).</p> <p><bold>Заключение.</bold> Двухэтапный подход к интервенционному лечению сопутствующих ФП и типичного ТП обеспечивает более эффективное удержание синусового ритма по сравнению с одноэтапным подходом (94,12 и 52,94% соответственно; p=0,001). Изолированная РЧА КТП при сопутствующих ФП и типичном ТП ассоциирована с рецидивом ФП в 23,53% случаев и характеризуется меньшей продолжительностью вмешательства и рентгеноскопии по сравнению с подходом, при котором одномоментно выполняется ИЛВ и РЧА КТП (p &lt;0,001).</p></trans-abstract><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>typical atrial flutter</kwd><kwd>radiofrequency catheter ablation</kwd><kwd>cavotricuspid isthmus</kwd><kwd>pulmonary vein isolation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>типичное трепетание предсердий</kwd><kwd>радиочастотная катетерная абляция</kwd><kwd>кавотрикуспидальный перешеек</kwd><kwd>изоляция лёгочных вен</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Celikyurt U, Knecht S, Kuehne M, et al. Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter. Europace. 2017;19(11):1776–1780. doi: 10.1093/europace/euw343</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bertaglia E, Bonso A, Zoppo F, et al. Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter. Pacing Clin Electrophysiol. 2004;27(11):1507–1512. doi: 10.1111/j.1540-8159.2004.00668.x</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: Electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart. 2001;85(4):424–429. doi: 10.1136/heart.85.4.424</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Enriquez A, Sarrias A, Villuendas R, et al. New-onset atrial fibrillation after cavotricuspid isthmus ablation: identification of advanced interatrial block is key. Europace. 2015;17(8): 1289–1293. doi: 10.1093/europace/euu379</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Krisai P, Roten L, Zelijkovic I, et al. Prospective evaluation of a standardized screening for atrial fibrillation after ablation of cavotricuspid isthmus dependent atrial flutter. J Clin Med. 2021;10(19):4453. doi: 10.3390/jcm10194453</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Page RL, Joglar JA, Caldwell MA, et al. ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: A report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e471–e505. doi: 10.1161/CIR.0000000000000310</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bastani H, Drea N, Insulander P, et al. Cryothermal vs radiofrequency ablation as atrial flutter therapy: A randomized comparison. Europace. 2013;15(3):420–428. doi: 10.1093/europace/eus261</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cox JL, Canavan TE, Schuessler RB, et al. The surgical treatment of atrial fibrillation: II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thoracic Cardiovasc Surg. 1991;101(3):406–426.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chinitz JS, Gerstenfeld EP, Marchlinsky FE, et al. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up. Heart Rhythm. 2007;4(8):1029–1033. doi: 10.1016/j.hrthm.2007.04.002</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mittal S, Pokushalov E, Romanov A, et al. Long-term ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid isthmus ablation in patients with atrial flutter. Heart Rhythm. 2013;10(11):1598–1604. doi: 10.1016/j.hrthm.2013.07.044</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ellis K, Wazni O, Marrouche N, et al. Incidence of atrial fibrillation post‐cavotricuspid isthmus ablation in patients with typical atrial flutter: Left‐atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2007;18(8):799–802. doi: 10.1111/j.1540-8167.2007.00885.x</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Luria DM, Hodge DO, Monahan KH, et al. Effect of radiofrequency ablation of atrial flutter on the natural history of subsequent atrial arrhythmias. J Cardiovasc Electrophysiol. 2008;19(11):1145–1150. doi: 10.1111/j.1540-8167.2008.01206.x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Romanov A, Pokushalov E, Bayramova S, et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: Three‐year outcomes of the PREVENT AF I study. J Cardiovasc Electrophysiol. 2018;29(6):872–878. doi: 10.1111/jce.13485</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Schmieder S, Ndrepepe G, Dong J, et al. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J. 2003;24(10): 956–962. doi: 10.1016/s0195-668x(02)00846-1</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bandini A, Golia P, Caroli E. et al. Atrial fibrillation after typical atrial flutter ablation: A long-term follow-up. J Cardiovasc Med. 2011;12(2):110–115. doi: 10.2459/JCM.0b013e3283403301</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gula LJ, Scanes AC, Klein GJ, et al. Atrial flutter and atrial fibrillation ablation: Sequential or combined? A cost-benefit and risk analysis of primary prevention pulmonary vein ablation. Heart Rhythm. 2016;13(7):1441–1448. doi: 10.1016/j.hrthm.2016.02.018</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation. Circulation. 2003; 108:2479–2483. doi: 10.1161/01.CIR.0000101684.88679.AB</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Steinberg JS, Romanov A, Musat D, et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: The PReVENT AF Study I. Heart Rhythm. 2014;11(9):1567–1572. doi: 10.1016/j.hrthm.2014.05.011</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bianco I, Silva GO, Forno AR, et al. Risk of atrial fibrillation after ablation of cavotricuspid isthmus-dependent atrial flutter: Is combined ablation of atrial fibrillation worthwhile? Arquivos Brasileiros Cardiologia. 2020;114:775–782. doi: 10.36660/abc.20190238</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Laurent V, Fauchier L, Pierre B, et al. Incidence and predictive factors of atrial fibrillation after ablation of typical atrial flutter. J Interv Card Electrophysiol. 2009;24:119–125. doi: 10.1007/s10840-008-9323-1</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Brembilla-Perrot B, Girerd N, Sellal JM, et al. Risk of atrial fibrillation after atrial flutter ablation: Impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol. 2014;25:813–820. doi: 10.1111/jce.12413</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Pontoppidan J, Nielsen JC, Poulsen SH, et al. Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: A randomised controlled trial. Heart. 2009;95(12):994–999. doi: 10.1136/hrt.2008.153965</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Koerber SM, Turagam MK, Gautam S, et al. Prophylactic pulmonary vein isolation during cavotricuspid isthmus ablation for atrial flutter: A meta-analysis. Pacing Clin Electrophysiol. 2019;42(5):493–498. doi: 10.1111/pace.13637</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mesquita J, Ferreira AM, Cavaco D, et al. Impact of prophylactic cavotricuspid isthmus ablation in atrial fibrillation recurrence after a first pulmonary vein isolation procedure. Int J Cardiol. 2018;259:82–87. doi: 10.1016/j.ijcard.2018.01.025</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mohanty S, Mohanty P, di Biase L, et al. Results from a single-blind, randomized study comparing the impact of different ablation approaches on long-term procedure outcome in coexistent atrial fibrillation and flutter (APPROVAL). Circulation. 2013;127(18): 1853–1860. doi: 10.1161/CIRCULATIONAHA.113.001855</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sealed Envelope Ltd. 2012. Power calculator for binary outcome superiority trial [Accessed Sat Feb 18 2023]. Режим доступа: https://sealedenvelope.com/power/binary-superiority/. Дата обращения: 18.02.2023.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Pérez FJ, Schubert CM, Parvec B, et al. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: A meta-analysis. Circulation Arrhythmia Electrophysiol. 2009;2(4):393–401. doi: 10.1161/CIRCEP.109.871665</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Taghji P, El Haddad M, Phlips T, et al. Evaluation of a strategy aiming to enclose the pulmonary veins with contiguous and optimized radiofrequency lesions in paroxysmal atrial fibrillation: A pilot study. JACC Clin Electrophysiol. 2018;4(1):99–108. doi: 10.1016/j.jacep.2017.06.023</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Зотов А.С., Хамнагадаев И.А., Сахаров Э.Р., и др. Первый опыт применения гибридного подхода при хирургическом лечении фибрилляции предсердий // Клиническая практика. 2022. Т. 13, № 4. С. 38–50. [Zotov AS, Khamnagadaev IA, Sakharov ER, et al. The first experience of using a hybrid approach in the surgical treatment of atrial fibrillation. J Clin Pract. 2022;13(4):38–50. (In Russ).] doi: 10.17816/clinpract116052</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Mohanty S, Natale A, Mohanty P, et al. Pulmonary vein isolation to reduce future risk of atrial fibrillation in patients undergoing typical flutter ablation: Results from a randomized pilot study (REDUCE AF). J Cardiovasc Electrophysiol. 2015;26(8):819–825. doi: 10.1111/jce.12688</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Cox JL, Schuessler RB, Boineau JP. The surgical treatment of atrial fibrillation. I. Summary of the current concepts of the mechanisms of atrial flutter and atrial fibrillation. J Thoracic Cardiovascular Surg. 1991;101(3):402–405.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Dechering DG, Gonska BD, Brachmann J, et al. Efficacy and complications of cavotricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: Results from the German Ablation Registry. J Int Cardiac Electrophysiol. 2021;61(1):55–62. doi: 10.1007/s10840-020-00769-z</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Schneider R, Lauschke J, Tischer T, et al. Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial. Heart Rhythm. 2015; 12(5):865–871. doi: 10.1016/j.hrthm.2015.01.040</mixed-citation></ref></ref-list></back></article>
